GAMMA Investing LLC Has $20.48 Million Stock Holdings in Masimo Co. (NASDAQ:MASI)

GAMMA Investing LLC lifted its position in Masimo Co. (NASDAQ:MASI - Free Report) by 26,284.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 122,951 shares of the medical equipment provider's stock after acquiring an additional 122,485 shares during the period. GAMMA Investing LLC owned about 0.23% of Masimo worth $20,484,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Barclays PLC grew its position in Masimo by 152.6% during the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after purchasing an additional 24,137 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. Greenleaf Trust acquired a new stake in shares of Masimo in the fourth quarter worth $208,000. Trust Point Inc. purchased a new position in shares of Masimo during the fourth quarter valued at $230,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in Masimo by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider's stock valued at $61,773,000 after buying an additional 1,522 shares during the period. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Up 4.4%

NASDAQ MASI traded up $7.25 during trading on Friday, reaching $171.97. The company's stock had a trading volume of 910,113 shares, compared to its average volume of 644,718. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $9.32 billion, a PE ratio of 118.60 and a beta of 1.19. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The business has a 50-day moving average price of $157.05 and a 200-day moving average price of $167.29.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same period in the prior year, the company posted $0.77 earnings per share. Masimo's revenue for the quarter was down 24.5% on a year-over-year basis. On average, research analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,053 shares of company stock valued at $6,998,565. Company insiders own 9.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on MASI shares. BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Wells Fargo & Company decreased their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Raymond James dropped their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $200.00 target price (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $191.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.